Anticentromere antibody and immunoglobulin allotypes in scleroderma

Area of Science:

• Immunology
• Rheumatology
• Genetics

Background:

• Scleroderma spectrum disorders are autoimmune diseases characterized by connective tissue hardening.
• Antinuclear antibodies (ANA) and Raynaud's phenomenon (RP) are common in scleroderma.
• Anticentromere antibody (ACA) is a specific ANA subtype associated with certain scleroderma manifestations.

Purpose of the Study:

• To investigate the association between anticentromere antibody (ACA) and clinical features in patients with scleroderma spectrum disorders.
• To explore the relationship between ACA, the CREST syndrome, and organ system involvement.
• To examine potential associations between Gm and Km allotypic markers and scleroderma or ACA.

Main Methods:

• Study included 55 unrelated white patients with scleroderma spectrum disorders, ANA, and RP.
• Patients were categorized based on the presence and type of antinuclear antibodies (ACA vs. other nuclear patterns).
• Clinical data, including organ system involvement and CREST syndrome manifestations, were collected and analyzed. Gm and Km allotypic markers were also assessed.

Main Results:

• Of 55 patients, 22 had ACA (3 diffuse scleroderma, 16 CREST syndrome, 3 RP only).
• 33 patients with other nuclear patterns had systemic scleroderma (28 diffuse, 5 CREST syndrome).
• ACA-positive patients showed trends towards less organ involvement and fewer CREST features compared to ACA-negative patients, though not statistically significant. No association was found between allotypic markers and scleroderma or ACA.

Conclusions:

• Anticentromere antibody (ACA) in scleroderma patients is associated with a tendency towards fewer CREST syndrome manifestations and less organ system involvement.
• The presence of Gm and Km allotypic markers is not associated with scleroderma or the presence of ACA in this cohort.
• Further research may clarify the specific clinical implications of ACA in the scleroderma spectrum.